Gunderson Dettmer represented Sofinnova as it led the $55 million Series A financing of Atsena Therapeutics, a clinical-stage gene therapy company.

In the announcement of the transaction Partner of Sofinnova Dr. Sarah Bhagat said, “We believe Atsena’s foundation in ocular gene therapy and potentially game-changing novel AAV vectors position the company to become a partner of choice. Sofinnova is delighted to support Atsena and we look forward to helping the team further its mission to develop life-changing gene therapies for patients with inherited retinal diseases.”

The Gunderson deal team was led by Bennett Yee and included Gina Marek, Michelle Lee, Scout Moran and Joseph McGinley.